Notes: The Newcastle-Ottawa scale uses a star system (0 to 9) to evaluate included studies on 3 domains: selection, comparability, and outcomes. Star (*)= item presents. Maximum 1 star (*) for selection and outcome components and 2 stars (**) for comparability components. Higher scores represent higher study quality.
Supplementary Figure S1:
Forrest plot (excluding studies with potentially included duplicate patients) evaluating for the incidence of aHUS recurrence among patients who received prophylactic eculizumab (The pooled estimated incidence 7.0% (95%CI: 2.5%-18.1%, I 2 =0%)).
Supplementary Figure S2:
Forrest plot (excluding studies with potentially included duplicate patients) evaluating for the incidence of allograft loss due to TMA among patients who received prophylactic eculizumab (The pooled estimated incidence 5.3% (95%CI: 2.4%-11.3%, I 2 =0%). 
Group by

Supplementary Figure S3:
Forrest plot (excluding studies with potentially included duplicate patients) evaluating for the incidence of allograft loss due to all causes among patients who received eculizumab treatment (The pooled estimated incidence 26.7% (95%CI: 13.0%-46.9%, I 2 =33%)).
Supplementary Figure S4:
Forrest plot (excluding studies with potentially included duplicate patients) evaluating for the incidence of allograft loss due to all causes among patients who received eculizumab treatment (The pooled estimated incidence 20.0% (95%CI: 9.1%-38.4%, I 2 = 29%)). 
